ATE311198T1 - Pharmazeutische zusammensetzung enthaltend einen faktor viia und einen tfpi-inhibitor - Google Patents

Pharmazeutische zusammensetzung enthaltend einen faktor viia und einen tfpi-inhibitor

Info

Publication number
ATE311198T1
ATE311198T1 AT01931460T AT01931460T ATE311198T1 AT E311198 T1 ATE311198 T1 AT E311198T1 AT 01931460 T AT01931460 T AT 01931460T AT 01931460 T AT01931460 T AT 01931460T AT E311198 T1 ATE311198 T1 AT E311198T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
composition containing
factor viia
tfpi inhibitor
tfpi
Prior art date
Application number
AT01931460T
Other languages
English (en)
Inventor
Marianne Kjalke
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Application granted granted Critical
Publication of ATE311198T1 publication Critical patent/ATE311198T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT01931460T 2000-05-10 2001-05-10 Pharmazeutische zusammensetzung enthaltend einen faktor viia und einen tfpi-inhibitor ATE311198T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000771 2000-05-10
DKPA200000778 2000-05-10
DKPA200000871 2000-06-06
PCT/DK2001/000324 WO2001085199A1 (en) 2000-05-10 2001-05-10 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A TFPI INHIBITOR

Publications (1)

Publication Number Publication Date
ATE311198T1 true ATE311198T1 (de) 2005-12-15

Family

ID=27222387

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01931460T ATE311198T1 (de) 2000-05-10 2001-05-10 Pharmazeutische zusammensetzung enthaltend einen faktor viia und einen tfpi-inhibitor
AT01931458T ATE300953T1 (de) 2000-05-10 2001-05-10 Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01931458T ATE300953T1 (de) 2000-05-10 2001-05-10 Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen

Country Status (17)

Country Link
US (3) US20030092627A1 (de)
EP (3) EP1593389A1 (de)
JP (2) JP2004505016A (de)
CN (1) CN1304049C (de)
AT (2) ATE311198T1 (de)
AU (3) AU5822801A (de)
BR (1) BR0110659A (de)
CA (1) CA2406583A1 (de)
CZ (1) CZ20023667A3 (de)
DE (2) DE60115422T2 (de)
DK (1) DK1282438T3 (de)
ES (2) ES2254414T3 (de)
HU (1) HUP0301868A3 (de)
IL (1) IL152554A0 (de)
NO (1) NO20025355L (de)
PL (1) PL365042A1 (de)
WO (2) WO2001085198A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE464062T1 (de) * 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP1319067A2 (de) * 2000-09-13 2003-06-18 Novo Nordisk A/S Varianten des menschlichen koagulationsfaktors vii
US7176288B2 (en) 2000-09-13 2007-02-13 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
CA2427535A1 (en) * 2000-11-03 2002-05-10 Zymogenetics, Inc. Use of blood coagulation factor xiii for treating haemophilia a
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
EP1351706B1 (de) * 2000-11-10 2007-07-25 ZymoGenetics, Inc. Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b
WO2002062377A2 (en) * 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor viii polypeptides
CA2438761A1 (en) * 2001-02-21 2002-09-06 Zymogenetics, Inc. Method for treating von willebrand's disease
IL160703A0 (en) * 2001-09-10 2004-08-31 Zymogenetics Inc Method for treating coumarin-induced hemorrhage
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
JP2006510568A (ja) * 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
EP1446147A1 (de) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmazeutische zusammensetzung, die faktor vii polypeptide und tranexamsäure enthält
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
KR101006070B1 (ko) * 2001-12-21 2011-01-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드의 액체 조성물
AU2003240438A1 (en) 2002-06-21 2004-01-06 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
ATE424215T1 (de) 2003-01-08 2009-03-15 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
ATE547114T1 (de) 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
CA2534028A1 (en) 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
CN1863908B (zh) 2003-09-09 2010-08-04 诺和诺德医疗保健公司 凝固因子ⅶ多肽
WO2005107795A1 (en) * 2004-05-11 2005-11-17 Novo Nordisk Health Care Ag Use of factor viia for the treatment of burn traumas
WO2005115442A1 (en) * 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
WO2006021584A2 (en) * 2004-08-27 2006-03-02 Novo Nordisk Health Care Ag Purification of factor xiii polypeptides from biological materials
BRPI0515163A (pt) * 2004-09-10 2008-07-08 Pharmaorigin Aps métodos para tratar hemoptise ou sangramento traqueal, brÈnquico ou alveolar local
JP5086093B2 (ja) 2004-11-23 2012-11-28 ジモジェネティクス、インコーポレイテッド 組換え型ヒトｘｉｉｉ因子の精製
JP5236952B2 (ja) * 2005-02-28 2013-07-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 改善された特性を有するｆｘｉｉｉバリアント
EP1919499A2 (de) * 2005-07-29 2008-05-14 Universiteit van Maastricht Regulierung von gewebefaktoraktivität durch proteine und tfpi (tissue factor pathway inhibitor)
EP2004214B1 (de) * 2006-03-16 2012-11-07 STELLARIS PHARMACEUTICALS Aps Lokale behandlung mit faktor vii
WO2008009635A2 (en) * 2006-07-17 2008-01-24 Novo Nordisk Health Care Ag Factor viia analogues with increased activity for treating thrombocytopenia
NZ579985A (en) * 2007-04-13 2012-02-24 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
WO2009130181A2 (en) 2008-04-21 2009-10-29 Novo Nordisk Health Care Ag Dry transglutaminase composition
EP2149603A1 (de) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und ihre Verwendung zur Behandlung von Blutungsstörungen
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
BRPI0922344A2 (pt) * 2008-12-19 2017-10-24 3B Pharmaceuticals Gmbh inibidores de tfpi e métodos de uso
WO2011115712A2 (en) 2010-03-19 2011-09-22 Baxter International Inc Tfpi inhibitors and methods of use
AR082588A1 (es) * 2010-08-05 2012-12-19 Council Scient Ind Res Construcciones de proteinas de fusion con propiedades tromboliticas y anticoagulantes
CN104302306B (zh) 2012-03-21 2019-03-22 百深有限责任公司 Tfpi抑制剂及其使用方法
EP2881463A1 (de) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und/oder mit erhöhter F.IX-Gerinnungsaktivität und ihre Verwendung zur Behandlung von Blutungsstörungen
JP6559188B2 (ja) * 2017-07-06 2019-08-14 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) * 2017-09-04 2018-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018108089A (ja) * 2018-02-19 2018-07-12 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
WO2020021890A1 (ja) * 2018-07-25 2020-01-30 ソニー株式会社 血液凝固系解析装置
JP6848016B2 (ja) * 2019-07-16 2021-03-24 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221780A (en) * 1978-12-04 1980-09-09 Cort Joseph H Method for producing high potency factor VIII
AU593042B2 (en) * 1985-11-26 1990-02-01 Novo Nordisk Health Care Ag Compositions and methods for the treatment of bleeding disorders
US5622988A (en) * 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
WO1993006855A1 (en) * 1991-10-11 1993-04-15 Novo Nordisk A/S Hemostatic composition for local hemostasis
CA2127107C (en) * 1991-12-31 2007-06-19 Bruce L. A. Carter Methods and compositions for reducing blood loss
WO1994002172A1 (en) * 1992-07-24 1994-02-03 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
DE4429118C2 (de) * 1994-08-17 1997-01-16 Siemens Ag Radarsensor
EP0885020A1 (de) * 1996-02-20 1998-12-23 Cohesion Corporation Verbindungen zum gewebeverschluss und methoden zu deren gebrauch
AU7907398A (en) * 1997-06-23 1999-01-04 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
WO1999032143A1 (en) * 1997-12-23 1999-07-01 Nuvas Llc Thrombogenic polypeptide chimeras and conjugates having activity dependent upon association with tumor vascular endothelium
JP2002514433A (ja) * 1998-05-14 2002-05-21 バッテル メモリアル インスティテュート トランスジェニック植物由来ヒト凝血因子
EP1148427A1 (de) * 2000-04-21 2001-10-24 Koninklijke KPN N.V. Methode und System zur Erzeugung eines Lesezeichen-Knopfs in einem Web-Browser mit der Darstellung eines vom Benutzer ausgewählten Teils der zugehörigen Datei
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
WO2002062377A2 (en) * 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor viii polypeptides
US20060025336A1 (en) * 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
US20030119741A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
JP2006510568A (ja) * 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
JP2005510515A (ja) * 2001-11-09 2005-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびプロテインｃ阻害剤を含む薬学的組成物
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides

Also Published As

Publication number Publication date
EP1282439A1 (de) 2003-02-12
US20070280920A1 (en) 2007-12-06
NO20025355D0 (no) 2002-11-08
US20060199766A1 (en) 2006-09-07
EP1282439B1 (de) 2005-11-30
CN1304049C (zh) 2007-03-14
ATE300953T1 (de) 2005-08-15
IL152554A0 (en) 2003-05-29
HUP0301868A2 (hu) 2003-08-28
WO2001085198A1 (en) 2001-11-15
CZ20023667A3 (cs) 2003-04-16
WO2001085199A1 (en) 2001-11-15
DE60115422T2 (de) 2006-08-17
JP2003532684A (ja) 2003-11-05
EP1593389A1 (de) 2005-11-09
PL365042A1 (en) 2004-12-27
NO20025355L (no) 2003-01-09
DE60115422D1 (de) 2006-01-05
ES2247106T3 (es) 2006-03-01
AU2001258230A1 (en) 2001-11-20
DE60112429T2 (de) 2006-06-01
CN1429117A (zh) 2003-07-09
DK1282438T3 (da) 2005-11-14
ES2254414T3 (es) 2006-06-16
BR0110659A (pt) 2003-02-11
HUP0301868A3 (en) 2006-11-28
EP1282438A1 (de) 2003-02-12
AU2001258228B2 (en) 2006-01-12
CA2406583A1 (en) 2001-11-15
EP1282438B1 (de) 2005-08-03
US20030092627A1 (en) 2003-05-15
AU5822801A (en) 2001-11-20
JP2004505016A (ja) 2004-02-19
DE60112429D1 (de) 2005-09-08

Similar Documents

Publication Publication Date Title
DE60115422D1 (de) PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR
SE0102315D0 (sv) Compounds
ATE380054T1 (de) Topisches mittel zur dermatologischen verwendung enthaltend 4-hydroxyphenyl-alpha-d-glucopyranosid
AR027968A1 (es) Una composicion para utilizar en el tratamiento y/o prevencion del sarampion y el uso de dicha composicion para un vehiculo para el tratamiento o prevencion del sarampion
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
ATE217187T1 (de) Neue pharmazeutische zusammensetzung, die den ace-hemmer ramipril und eine dihydropyridin- verbindung enthält
EE200100618A (et) Dieet- või farmatseutiline kompositsioon kasutamiseks hüperoksaluuria vältimiseks või raviks
ATE331500T1 (de) Synergistische orale zusammensetzung gegen zahnbelag und gingivitis
DK0609606T3 (de)
DE60016460D1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
ATE302746T1 (de) Amorphe salpetersäureester und deren pharmazeutische zusammensetzungen
FI935172A7 (fi) Katepsiini G:n ja elastaasin inhibiittoreita sidekudoksen rappeutumise n ehkäisemistä varten
IL145684A0 (en) Treatment of pulmonary hypertension
ATE315395T1 (de) Pharmazeutische zusammensetzungen, die faropenem natrium und eine diamineacetat verbindung zur verbesserung der magen-darm trakt absorption enthalten
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
IT1318556B1 (it) Composizione farmaceutica a base di prolina, glicina e lisina utilenella terapia per la cicatrizzazione delle ferite e delle lesioni
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
BR8000753U (pt) Balão de inflar para decoração e folguedos
ATE314073T1 (de) Kombination von aktiva mit alfuzosin und apomorphin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties